NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Clinical Trials
36 trialsNCT07310784 2026-03-03
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
NCT06703398 2025-12-23
MIZAR-003
Shanghai Juncell Therapeutics
Phase 2 Recruiting
NCT01152788 2023-08-22
Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01835145 2022-08-04
Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00130442 2022-06-23
Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Cellxpert Biotechnology Corp.
Phase 2 Completed
NCT00553618 2021-10-29
DTIC
University of Louisville
Phase 2 Active not recruiting
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04200040 2020-02-27
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
OrienGene Biotechnology Ltd.
Phase 2 Unknown
NCT02190838 2019-11-25
Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma
N.N. Petrov National Medical Research Center of Oncology
Phase 2 Terminated
NCT01551459 2019-10-29
SUAVE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Completed
NCT01100528 2019-02-26
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01542255 2019-01-15
Metronomic Therapy in Patients With Metastatic Melanoma
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT01693068 2018-01-05
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
EMD Serono
Phase 2 Completed
NCT01143402 2017-07-26
Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Completed
NCT00849875 2017-07-12
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
GlaxoSmithKline
Phase 2 Terminated
NCT01164007 2017-04-21
A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01705392 2017-02-24
Bevacizumab vs Dacarbazine in Metastatic Melanoma
Haukeland University Hospital
Phase 2 Terminated
NCT00936221 2016-03-14
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
Phase 2 Completed
NCT01028222 2015-12-30
TEAM
Novartis
Phase 2 Completed
NCT01376713 2015-10-06
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Medical University of Vienna
Phase 2 Completed
NCT01681212 2015-06-11
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed
NCT00492297 2014-10-31
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00533702 2014-08-01
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Eli Lilly and Company
Phase 2 Completed
NCT01055522 2014-02-25
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Philogen S.p.A.
Phase 2 Terminated
NCT00004141 2013-09-05
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma
University of Chicago
Phase 2 Completed
NCT00002669 2012-07-02
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00991250 2010-02-05
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
SentoClone AB
Phase 2 Unknown
NCT00794235 2010-01-08
Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine
University of Zurich
Phase 2 Completed
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed
NCT00308607 2009-04-03
Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma
University of Turku
Phase 2 Completed
NCT00070642 2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2 Completed
NCT00099970 2008-08-05
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
Facet Biotech
Phase 2 Completed
NCT00066196 2008-01-15
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
MedImmune LLC
Phase 2 Completed
NCT00006200 2005-06-24
Thalidomide and Dacarbazine for Metastatic Melanoma
National Center for Research Resources (NCRR)
Phase 2 Unknown